CNS Pharmaceuticals Received Letter From Nasdaq Notifying Co That It Had Regained Compliance With Bid Price Rule
$CNSP
Biotechnology: Pharmaceutical Preparations
Health Care
- SEC Filing
- SEC Filing
Save time and jump to the most important pieces.
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment.As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2).About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and meta
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share.The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction
SC 13D - CNS Pharmaceuticals, Inc. (0001729427) (Subject)
SC 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)
SC 13G - CNS Pharmaceuticals, Inc. (0001729427) (Subject)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
DEF 14A - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunologyHOUSTON, TX / ACCESSWIRE / January 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, a $9 Billion market cap b
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, Jan. 3, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Faith L. Charles as Chair of its Board of Directors. "The depth and breadth of knowledge, experience and network that Fait
LAS VEGAS, March 16, 2021 /PRNewswire/ -- Esports Technologies, Inc., a global provider of advanced esports wagering products, today announced the appointment of Christopher Downs to its Board of Directors, effective March 5, 2021. Downs will lend his years of corporate finance experience to Esports Technologies as it accelerates its growth in esports wagering. As a board member of Esports Technologies, Downs will chair the Audit Committee and serve on both the Compensation and Nominating and Governance Committees. Esports Technologies Adds Deep Expertise in Corporate Finance and Operations With Appointment of Christopher Downs to its Board of Directors Aaron Speach, Esp
Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00
- SEC Filing
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. The company's market cap stands at $1.5 million. The company's, Q1 earnings came out 2 days ago. Sharps Technology (NASDAQ:STSS) stock rose 33.56% to $0.31. The market value of their outstanding shares is at $6.1 million. Autonomix Medical (NASDAQ:AMIX) shares increased by 21.43% to $0.78. The market value of their outstanding shares is at $14.6 million. Akso Health Group (NASDAQ:AHG) stock rose 11.68% to $1.29. The company's market cap stands at $189.2 million. Conduit Pharmaceuticals (NASDAQ:CDT) stock rose 10.74% to $0.71. The company's market cap stands at $52.3 mill